Chorionic Gonadotropin

openFDA label record#

Cross-check layer: This is openFDA JSON-derived label data. Use the corresponding DailyMed SPL as the canonical label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: Chorionic Gonadotropin
Generic name: CHORIONIC GONADOTROPIN
Manufacturer: NuCare Pharmaceuticals,Inc.
Product type: HUMAN PRESCRIPTION DRUG
SPL set ID: 312ee87a-c6c3-6111-e063-6394a90ad8d7
SPL ID: 312ef3fd-bb47-dd83-e063-6294a90a262a
Version: 1
Effective date: 2025-03-25
Source export date: 2026-08-01
Source partition: 11
Source file: https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-08-01/8ac060fefb6f4d67c41cc2c9e4330286ca93c48094c18386c11bf706a1d8bd34/drug-label-0011-of-0014.json.zip
Source manifest SHA-256: bdd1454d0606b622b70458a306b8a10d8a8787db06fd9f46e69c7f7a4524b630
Import run: 20260801T225920Z
Imported at: 2026-08-01 23:27:37

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application applno	BLA	017067	derived:openfda.application_number
application number		BLA017067	openfda.application_number
brand name		Chorionic Gonadotropin	openfda.brand_name
generic name		CHORIONIC GONADOTROPIN	openfda.generic_name
manufacturer name		NuCare Pharmaceuticals,Inc.	openfda.manufacturer_name
ndc	package	68071-3815-1	openfda.package_ndc
ndc	product	68071-3815	openfda.product_ndc
ndc11	package	68071381501	derived:openfda.package_ndc
rxcui		896854	openfda.rxcui
spl id		312ef3fd-bb47-dd83-e063-6294a90a262a	id
spl set id		312ee87a-c6c3-6111-e063-6394a90ad8d7	set_id

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS: HCG should be used in conjunction with human menopausal gonadotropins only by physicians experienced with infertility problems who are familiar with the criteria for patient selection, contraindications, warnings, precautions and adverse reactions described in the package insert for menotropins. The principal serious adverse reactions are: (1) Ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain and/or pleural effusion, (2) Rupture of ovarian cysts with resultant hemoperitoneum, (3) Multiple births and (4) Arterial thromboembolism. Anaphylaxis and other hypersensitivity reactions have been reported with urinary-derived HCG products.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS: Headache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia and pain at the site of injection.